Skip to content
lifestyle.streetregister.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Black Diamond Therapeutics, Inc
Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC
November 9, 2026
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
September 2, 2026
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 5, 2026
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
May 25, 2026
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
May 25, 2026
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
May 24, 2026